121 related articles for article (PubMed ID: 34116872)
1. Serum antibody levels to pneumococcal polysaccharides 22F, 33F, 19A and 6A that correlate with protection from colonization and acute otitis media in children.
Kaur R; Pham M; Pichichero M
Vaccine; 2021 Jun; 39(29):3900-3906. PubMed ID: 34116872
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and protective efficacy of monovalent PCVs containing 22F and 33F polysaccharides in mouse models of colonization and co-infection.
Khan MN; Pryharski K; Pichichero ME
Vaccine; 2018 Sep; 36(38):5701-5708. PubMed ID: 30107993
[TBL] [Abstract][Full Text] [Related]
3. Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes.
Amin-Chowdhury Z; Groves N; Sheppard CL; Litt D; Fry NK; Andrews N; Ladhani SN
Vaccine; 2021 Apr; 39(14):1997-2004. PubMed ID: 33715901
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis of Streptococcus pneumoniae serotype 3 during natural colonization and infections among children and its IgG correlate of protection in a mouse model.
Fuji N; Pichichero M; Kaur R
Vaccine; 2022 Oct; 40(44):6412-6421. PubMed ID: 36192274
[TBL] [Abstract][Full Text] [Related]
5. The future of pneumococcal disease prevention.
Rodgers GL; Klugman KP
Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
[TBL] [Abstract][Full Text] [Related]
6. 20‑Valent Pneumococcal Conjugate Vaccine: Pediatric First Approval.
Shirley M
Paediatr Drugs; 2023 Sep; 25(5):613-619. PubMed ID: 37440125
[TBL] [Abstract][Full Text] [Related]
7. Naturally-induced serum antibody levels in children to pneumococcal polysaccharide 15B that correlate with protection from nasopharyngeal colonization but anti-serotype 15B antibody has low functional cross-reactivity with serotype 15C.
Kaur R; Gonzalez E; Pham M; Pichichero M
Vaccine; 2023 Nov; 41(48):7265-7273. PubMed ID: 37925318
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study.
Pichichero M; Kaur R; Scott DA; Gruber WC; Trammel J; Almudevar A; Center KJ
Lancet Child Adolesc Health; 2018 Aug; 2(8):561-568. PubMed ID: 30119715
[TBL] [Abstract][Full Text] [Related]
9. Acute otitis media caused by Streptococcus pneumoniae serotype 19A ST320 clone: epidemiological and clinical characteristics.
Chi H; Chiu NC; Huang FY; Hsu CH; Lee KS; Huang LM; Hsieh YC
J Microbiol Immunol Infect; 2018 Jun; 51(3):337-343. PubMed ID: 28087317
[TBL] [Abstract][Full Text] [Related]
10. Invasive Streptococcus pneumoniae in Canada, 2011-2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F.
Golden AR; Adam HJ; Zhanel GG;
Vaccine; 2016 May; 34(23):2527-30. PubMed ID: 27085174
[TBL] [Abstract][Full Text] [Related]
11. PCR-based discrimination of emerging Streptococcus pneumoniae serotypes 22F and 33F.
Gillis HD; Demczuk WHB; Griffith A; Martin I; Warhuus M; Lang ALS; ElSherif M; McNeil SA; LeBlanc JJ
J Microbiol Methods; 2018 Jan; 144():99-106. PubMed ID: 29162393
[TBL] [Abstract][Full Text] [Related]
12. Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines.
Rodgers GL; Arguedas A; Cohen R; Dagan R
Vaccine; 2009 Jun; 27(29):3802-10. PubMed ID: 19446378
[TBL] [Abstract][Full Text] [Related]
13. Correlation of higher antibody levels to pneumococcal proteins with protection from pneumococcal acute otitis media but not protection from nasopharyngeal colonization in young children.
Xu Q; Casey JR; Almudevar A; Pichichero ME
Clin Microbiol Infect; 2017 Jul; 23(7):487.e1-487.e6. PubMed ID: 28143785
[TBL] [Abstract][Full Text] [Related]
14. Evolving microbiology and molecular epidemiology of acute otitis media in the pneumococcal conjugate vaccine era.
Pichichero ME; Casey JR
Pediatr Infect Dis J; 2007 Oct; 26(10 Suppl):S12-6. PubMed ID: 18049375
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
Skinner JM; Indrawati L; Cannon J; Blue J; Winters M; Macnair J; Pujar N; Manger W; Zhang Y; Antonello J; Shiver J; Caulfield M; Heinrichs JH
Vaccine; 2011 Nov; 29(48):8870-6. PubMed ID: 21964055
[TBL] [Abstract][Full Text] [Related]
16. Multinational study of pneumococcal serotypes causing acute otitis media in children.
Hausdorff WP; Yothers G; Dagan R; Kilpi T; Pelton SI; Cohen R; Jacobs MR; Kaplan SL; Levy C; Lopez EL; Mason EO; Syriopoulou V; Wynne B; Bryant J
Pediatr Infect Dis J; 2002 Nov; 21(11):1008-16. PubMed ID: 12442021
[TBL] [Abstract][Full Text] [Related]
17. Modeling specific antibody responses to natural immunization to predict a correlate of protection against infection before commencing a clinical vaccine trial.
Almudevar A; Pichichero ME
Hum Vaccin Immunother; 2017 Oct; 13(10):2316-2321. PubMed ID: 28892455
[TBL] [Abstract][Full Text] [Related]
18. The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark.
Slotved HC; Dalby T; Hoffmann S
Vaccine; 2016 Feb; 34(6):769-74. PubMed ID: 26772630
[TBL] [Abstract][Full Text] [Related]
19. A novel immuno-molecular strategy for the detection of Streptococcus pneumoniae serotypes in human cerebrospinal and middle ear fluids.
Rajam G; Hicks KL; Antonello JM; Zhang Y; Irey S; Kelly J; Cooper S; Rubinstein LJ
J Immunol Methods; 2023 Aug; 519():113516. PubMed ID: 37348647
[TBL] [Abstract][Full Text] [Related]
20. Pneumococcal acute otitis media in infants and children in central Romania, 2009-2011: microbiological characteristics and potential coverage by pneumococcal conjugate vaccines.
Falup-Pecurariu O; Leibovitz E; Mercas A; Bleotu L; Zavarache C; Porat N; Dagan R; Greenberg D
Int J Infect Dis; 2013 Sep; 17(9):e702-6. PubMed ID: 23522635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
